mRNA technology news - the latest biotech news from Labiotech.eu

Unlocking the power of mRNA technology

External Contributor — Tue, 11 Jul 2023 07:57:29 +0000

By Yochi Slonim, CEO and co-founder of Anima Biotech mRNA technology has gained widespread recognition due to its role in the development of vaccines, such as those used against COVID-19; however, the scope of mRNA extends far beyond vaccines, offering a range of applications for addressing different conditions. Vaccines represent a notable application of mRNA […]

The post Unlocking the power of mRNA technology appeared first on Labiotech.eu.

© Labiotech UG and Labiotech.eu. Unauthorized use and/or duplication of this material without express and written permission from this site’s author and/or owner is strictly prohibited. Excerpts and links may be used, provided that full and clear credit is given to Labiotech UG and Labiotech.eu with appropriate and specific direction to the original content.

Inhaled mRNA medicines redefine respiratory disease treatment

External Contributor — Tue, 11 Jul 2023 07:35:17 +0000

By Carsten Rudolph, co-founder and CEO of Ethris Advancements in mRNA technology have led to the development of inhaled mRNA medicines, which hold tremendous potential for revolutionizing the treatment of respiratory diseases, an area with high unmet needs. However, the primary hurdle in its clinical application lies in the identification of a delivery system that […]

The post Inhaled mRNA medicines redefine respiratory disease treatment appeared first on Labiotech.eu.

“Ready-to-use” enzymatically produced cell-free synthetic DNA in mRNA manufacturing

External Contributor — Mon, 10 Jul 2023 14:36:43 +0000

By Ashish Dhir, PhD and Amy Walker, PhD, 4basebio The pace, efficacy and scalability with which the success of mRNA vaccines against COVID-19 was demonstrated opened endless possibilities for mRNA medicine in broad areas of infectious diseases, cancers, protein-encoding replacement therapies. The advantages of RNA medicine are obvious, with the ease and speed of design […]

The post “Ready-to-use” enzymatically produced cell-free synthetic DNA in mRNA manufacturing appeared first on Labiotech.eu.

Making an impact through targeting mRNA

Jim Cornall — Mon, 10 Jul 2023 12:00:00 +0000

Biotech company Molecure develops small molecule therapies that can regulate RNA and underexplored protein targets for the treatment of incurable diseases, including cancer and fibrotic and inflammatory diseases. The company, which was named as one of our 10 biotech companies leading the charge in Poland, told Labiotech that its RNA platform finds small molecules that […]

The post Making an impact through targeting mRNA appeared first on Labiotech.eu.

Unleashing the potential: Optimizing mRNA for the discovery of transformative medicines

External Contributor — Mon, 10 Jul 2023 09:34:05 +0000

By Dr. Alexander Zehnder, CEO, CureVac The success of mRNA vaccines in COVID-19 propelled the role of this new modality to the forefront of medicine. Not only are new prophylactic mRNA vaccines for various respiratory diseases advancing through clinical development, but mRNA medicines are now being developed in many wide-ranging applications, including cancer and rare […]

The post Unleashing the potential: Optimizing mRNA for the discovery of transformative medicines appeared first on Labiotech.eu.

Five innovations to take RNA vaccines to the next level

External Contributor — Mon, 10 Jul 2023 09:07:59 +0000

By Venkata Indurthi, PhD, chief scientific officer, Aldevron During the COVID-19 pandemic, the world turned to a previously unused vaccine technology to rapidly develop desperately needed vaccines, providing immunity to millions worldwide. These new vaccines made use of the body’s natural translational machinery, which turns mRNA encoding the SARS-Cov2 spike protein into an antigen that […]

The post Five innovations to take RNA vaccines to the next level appeared first on Labiotech.eu.

Can cardiovascular diseases be cured? The future of heart treatment

Willow Shah-Neville — Fri, 19 May 2023 14:01:04 +0000

Cardiovascular diseases, characterized as a group of disorders of the heart and blood vessels, are the leading cause of death worldwide. In fact, in the U.S. alone, it is thought that one person dies every 33 seconds from cardiovascular disease. Although clearly a huge health problem throughout the world, developing cures for cardiovascular diseases is […]

The post Can cardiovascular diseases be cured? The future of heart treatment appeared first on Labiotech.eu.

How is Quantoom Biosciences’ Ntensify™ technology changing mRNA production?

External Contributor — Thu, 04 May 2023 08:00:59 +0000

The post How is Quantoom Biosciences’ Ntensify™ technology changing mRNA production? appeared first on Labiotech.eu.

Eterna acquires allogeneic immuno-oncology platform from Exacis

Jim Cornall — Wed, 03 May 2023 14:26:47 +0000

Eterna Therapeutics Inc. has announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics. The acquisition complements Eterna Therapeutics’ core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna Therapeutics with an exclusive global license to produce an unlimited number of mRNA-engineered […]

The post Eterna acquires allogeneic immuno-oncology platform from Exacis appeared first on Labiotech.eu.

Can mRNA vaccines tackle multiple diseases?

External Contributor — Wed, 26 Apr 2023 10:04:01 +0000

By Dr. Myriam Mendila, chief development officer of CureVac World Immunization Week is April 24-30, and it’s an important week to highlight the action needed and to promote the use of vaccines to protect people around the world, of all ages, against infectious diseases. World Immunization Week aims to promote the use of vaccines to […]

The post Can mRNA vaccines tackle multiple diseases? appeared first on Labiotech.eu.

More efficient and cost-effective mRNA vaccines developed

Jim Cornall — Tue, 25 Apr 2023 10:32:56 +0000

A new and patented method for the production of the important mRNA vaccine component pseudouridine is more efficient, sustainable and cost-effective than the previously used chemical synthesis. Researchers from the Institute of Biotechnology and Biochemical Engineering at TU Graz and the Austrian Centre of Industrial Biotechnology (acib) have developed a novel method for the production […]

The post More efficient and cost-effective mRNA vaccines developed appeared first on Labiotech.eu.

mRNA vaccines: a promising future

Roohi Mariam Peter — Fri, 14 Apr 2023 15:18:54 +0000

In 1978, nearly two decades after the discovery of messenger RNA (mRNA), the concept of a vaccine made from mRNA was materialized. Like its name suggests, mRNAs are messengers that aid in decoding genetic information from DNA to synthesize proteins, a key cellular function. Previous attempts at developing a vaccine using mRNA failed because mRNA […]

The post mRNA vaccines: a promising future appeared first on Labiotech.eu.

Likang gets trial ok for China’s first personalized cancer vaccine

Jim Cornall — Fri, 17 Mar 2023 12:30:34 +0000

Likang Life Sciences has received implied approval for the clinical trial of its personalized neoantigen-targeted vaccine for advanced solid tumors, LK101 injection. This is the first personalized neoantigen vaccine and mRNA editing product approved by China’s Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) to enter the clinical stage. Likang submitted […]

The post Likang gets trial ok for China’s first personalized cancer vaccine appeared first on Labiotech.eu.

Could changing mRNA provide a new target for Alzheimer’s disease?

Jim Cornall — Wed, 08 Mar 2023 18:55:39 +0000

Reducing the methylation of a key messenger RNA can promote migration of macrophages into the brain and ameliorate symptoms of Alzheimer’s disease in a mouse model. This is according to a new study in the open access journal PLOS Biology by Rui Zhang of Air Force Medical University in Xian, Shaanxi, China. The results highlight […]

The post Could changing mRNA provide a new target for Alzheimer’s disease? appeared first on Labiotech.eu.

Moderna and Life Edit Therapeutics look to speed up gene editing therapies

Jim Cornall — Thu, 23 Feb 2023 10:26:34 +0000

Moderna, Inc., a biotechnology company working on messenger RNA (mRNA) therapeutics and vaccines, and Life Edit Therapeutics Inc., an ElevateBio company focused on gene editing technologies and therapeutics, have announced a strategic research and development collaboration to discover and develop in vivo mRNA gene editing therapies. The partnership will combine Life Edit’s suite of proprietary […]

The post Moderna and Life Edit Therapeutics look to speed up gene editing therapies appeared first on Labiotech.eu.

Beyond Biotech podcast 33: Astellas Pharma, Innovation Agency Lithuania, 4basebio

Jim Cornall — Fri, 10 Feb 2023 10:26:04 +0000

This week, our guests are Romualda Stragienė, director at Innovation Agency Lithuania and Andrius Sliuzas, export key account manager of high tech industries at Innovation Agency Lithuania; 4basebio CEO Heikki Lanckriet; and Yoshitsugu Shitaka, chief scientific officer at Astellas. 4basebio 4basebio, a spinout of 2Invest AG in 2020, is a life sciences company engaged in […]

The post Beyond Biotech podcast 33: Astellas Pharma, Innovation Agency Lithuania, 4basebio appeared first on Labiotech.eu.

AAHI bags $9.9M to develop nasal spray influenza RNA vaccine

Jim Cornall — Tue, 07 Feb 2023 09:40:15 +0000

The Access to Advanced Health Institute (AAHI) has been awarded a project agreement worth up to $9.9 million through the Medical CBRN Defense Consortium (MCDC) Other Transaction Authority (OTA) to develop a prototype intranasal bivalent influenza RNA vaccine candidate. The candidate will be based on AAHI’s self-amplifying RNA (saRNA) platform, which targets both pandemic A(H5N1) […]

The post AAHI bags $9.9M to develop nasal spray influenza RNA vaccine appeared first on Labiotech.eu.

Cancer Genomics: Technological innovation set to fuel research breakthroughs

External Contributor — Wed, 01 Feb 2023 07:47:00 +0000

By Neil Ward, vice President and general manager, PacBio EMEA We’ve known for a long time that genomic sequencing can strengthen our understanding of cancer’s highly complex and variable pathology. But to date, embedding genomics into cancer research has been challenging because of limitations in sequencing technology. But with recent innovations, this is changing. Genomic […]

The post Cancer Genomics: Technological innovation set to fuel research breakthroughs appeared first on Labiotech.eu.

Lupus treatment hope from Japanese miRNA research

Jim Cornall — Thu, 26 Jan 2023 09:10:44 +0000

A group of researchers from the Graduate School of Medicine at Nagoya University in Japan have discovered the impact of microRNA (miRNA) on inflammation in lupus in mice. They identified two miRNAs that are downregulated in the disease and an uncommon situation that occurs in which multiple miRNAs regulate the same set of genes. Although […]

The post Lupus treatment hope from Japanese miRNA research appeared first on Labiotech.eu.

Watch: pHion Therapeutics talks about next-generation mRNA vaccines

Jim Cornall — Mon, 23 Jan 2023 11:28:34 +0000

pHion Therapeutics is a U.K.-based vaccine development company. It is developing a pipeline of therapeutic and prophylactic vaccines focussed on viral infections and oncology. The company’s proprietary RALA platform can deliver anionic molecules, such as mRNA and DNA, in a stealth-like way, evading detection, to generate a potent antigen-specific CD8+ T-cell response. The RALA peptide-based […]

The post Watch: pHion Therapeutics talks about next-generation mRNA vaccines appeared first on Labiotech.eu.